Applied Filters
- Science and Policy
- Edwards, AledRemove filter
Journal Title
Publication Date
Author
- Gold, E Richard2
- Ali-Khan, Sarah E1
- Auld, Daniel1
- Bertier, Gabrielle1
- Breden, Felix1
- Bubela, Tania1
- Capps, Benjamin1
- Caron, Roxanne1
- Caulfield, Timothy1
- Chalaud, Damien1
- Cook-Deegan, Robert1
- César, Priscilla M D G1
- Doerr, Megan1
- Duncan, Ross1
- Goel, Vivek1
- Granados Moreno, Palmira1
- Issa, Amalia M1
- Joly, Yann1
- Morgan, Max1
- Mossman, Karen1
- Nickerson, Jason1
- Patrick, David1
- Rahimzadeh, Vasiliki1
- Reichman, Jerome1
Access Type
1 - 2of2
Save this search
Please login to be able to save your searches and receive alerts for new content matching your search criteria.
Filters
You do not have any saved searches
- OPEN ACCESS
- Palmira Granados Moreno,
- Sarah E. Ali-Khan,
- Benjamin Capps,
- Timothy Caulfield,
- Damien Chalaud,
- Aled Edwards,
- E. Richard Gold,
- Vasiliki Rahimzadeh,
- Adrian Thorogood,
- Daniel Auld,
- Gabrielle Bertier,
- Felix Breden,
- Roxanne Caron,
- Priscilla M.D.G. César,
- Robert Cook-Deegan,
- Megan Doerr,
- Ross Duncan,
- Amalia M. Issa,
- Jerome Reichman,
- Jacques Simard,
- Derek So,
- Sandeep Vanamala, and
- Yann Joly
Open science can significantly influence the development and translational process of precision medicine in Canada. Precision medicine presents a unique opportunity to improve disease prevention and healthcare, as well as to reduce health-related expenditures. However, the development of precision medicine also brings about economic challenges, such as costly development, high failure rates, and reduced market size in comparison with the traditional blockbuster drug development model. Open science, characterized by principles of open data sharing, fast dissemination of knowledge, cumulative research, and cooperation, presents a unique opportunity to address these economic challenges while also promoting the public good.The Centre of Genomics and Policy at McGill University organized a stakeholders’ workshop in Montreal in March 2018. The workshop entitled “Could Open be the Yellow Brick Road to Precision Medicine?” provided a forum for stakeholders to share experiences and identify common objectives, challenges, and needs to be addressed to promote open science initiatives in precision medicine. The rich presentations and exchanges that took place during the meeting resulted in this consensus paper containing key considerations for open science precision medicine in Canada. Stakeholders would benefit from addressing these considerations as to promote a more coherent and dynamic open science ecosystem for precision medicine. - OPEN ACCESS
- Tania Bubela,
- E. Richard Gold,
- Vivek Goel,
- Max Morgan,
- Karen Mossman,
- Jason Nickerson,
- David Patrick, and
- Aled Edwards
In the event of the current COVID-19 pandemic and in preparation for future pandemics, open science can support mission-oriented research and development, as well as commercialization. Open science shares skills and resources across sectors; avoids duplication and provides the basis for rapid and effective validation due to full transparency. It is a strategy that can adjust quickly to reflect changing incentives and priorities, because it does not rely on any one actor or sector. While eschewing patents, it can ensure high-quality drugs, low pricing, and access through existing regulatory mechanisms. Open science practices and partnerships decrease transaction costs, increase diversity of actors, reduce overall costs, open new, higher-risk/higher-impact approaches to research, and provide entrepreneurs freedom to operate and freedom to innovate. We argue that it is time to re-open science, not only in its now restricted arena of fundamental research, but throughout clinical translation. Our model and attendant recommendations map onto a strategy to accelerate discovery of novel broad-spectrum anti-viral drugs and clinical trials of those drugs, from first-in-human safety-focused trials to late stage trials for efficacy. The goal is to ensure low-cost and rapid access, globally, and to ensure that Canadians do not pay a premium for drugs developed from Canadian science.